CCRL2 and neoplasm: On day 15, to ensure balanced baseline tumor burdens, mice were stratified into groups with comparable bioluminescence signals and received anti-CCRL2 ADC or conjugated IgG2a (0.75 mg/kg, one dose) (Fig. 5A).